Cure8 research brief
Colonic delivery of oral ritlecitinib could concentrate drug where IBD inflammation often occurs while lowering systemic exposure. For people with UC or Crohn's disease, this research is an early step toward formulations that might target the colon more reliably across fed and fasted states.
Researchers and formulation scientists, clinicians interested in drug delivery approaches for IBD, and patients watching emerging oral JAK-targeted therapies.
This paper reports development of modified-release lipid microsphere formulations of ritlecitinib (a JAK3/TEC inhibitor) and uses human PK data plus physiologically based biopharmaceutics modeling (PBBM) to estimate how much of an oral dose is absorbed in each GI region.
In healthy volunteers, both faster- and slower-release MR formulations increased the fraction absorbed in the colon compared with an oral solution; food reduced colonic exposure for the faster-releasing formulation but not the slower one.
The report is based on an abstract/summary of a clinical study in healthy volunteers and model predictions rather than efficacy data in IBD patients. The trial identifiers (NCT06172348; EU CTR 2023-505603-23-00) are provided in the source.
If you are looking for treatment implications: this study addresses formulation and regional delivery, not clinical benefit or safety in Crohn's disease or UC. It suggests formulation release rate and prandial state matter for achieving consistent colonic delivery.
This is an abstract-level journal report and uses healthy volunteer PK and modeling to predict colon exposure; it does not provide patient efficacy or safety data in IBD. Ritlecitinib is a kinase inhibitor under investigation; this study focuses on drug delivery and pharmacokinetics rather than clinical outcomes.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of competing interest All contributing authors were employees of Pfizer Inc. at the initialization of the published work. Pfizer Inc. sponsored NCT06172348 / 2023-505603-23-00 and is the developer and commercial manufacturer of Litfulo™.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
Vedolizumab blood levels can vary with disease activity; a model that links intestinal α4β7 expression to drug exposure helps explain why some patients have lower drug levels and may need different dosing. This could...
Researchers are exploring a way to deliver biologic drugs directly in the gut using engineered B cells that become long-lived plasma cells. If successful, this could allow sustained, localized anti-inflammatory protein...
